Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy

Cell Cycle

Volumn 7, Issue 12, 2008, Pages 1870-1879

  Bossi, Gianluca ^a   Marampon, Francesco ^b   Maor Aloni, Revital ^c   Zani, Bianca ^b   Rotter, Varda ^c   Oren, Moshe ^c   Strano, Sabrina ^a   Blandino, Giovanni ^a   Sacchi, Ada ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Conditional RNAi; Gain of function; In vivo studies; Molecular targets; Mutant p53

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH;

ANIMALIA;

EID: 47249116180     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.12.6161     Document Type: Article

References (40)

1. Hainaut P and Hollestein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77:81-137.
2. Bullock AN and Fersht AR. Rescuing the function of mutant p53. Nat Rev Canc 2001; 1:68-76.
3. Harris SL and Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 17:2899-908.
4. Oren M. Decision making by p53: life, death and cancer. Cell Death Diff 2003; 4:413-42.
5. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2:811-4.
6. Blandino G, Levine AJ and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18:477-85.
7. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD. Mutant p53 cooperates with ETS and selectively upregulates human MDR1 not MRP1. J Biol Chem 2001; 276:39359-67.
8. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998; 18:3735-43.
9. Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003; 22:5667-76.
10. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004; 64:8318-27.
11. Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gein of function of mutant p53. Oncogene 2006; 25:359-69.
12. Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Canc.Res 2006; 66:6319-26.
13. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 199:861-72.
14. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse model of Li-Fraumeni syndrome. Cell 2004; 119:847-60.
15. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006; 25:304-9.
16. Brummelkamp TR, Bernerds R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550-3.
17. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002; 5:446-8.
18. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vectormediated drug-inducible RNA interference. J Virol 2003; 16:8957-61.
19. Deuschle U, Meyer WK, Thiesen HJ. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 1995; 4:1907-14.
20. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther 2006; 5:2435-43.
21. Bossi G, Mazzaro G, Porrello A, Crescenzi M, Soddu S, Sacchi A. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene 2004; 23:418-25.
22. Capponcelli S, Pedrini E, Cerone MA, Corti V, Fontanesi S, Alessio M, Bachi A, Soddu S, Ribatti D, Picci P, Helman LJ, Cantelli-Forti G, Sangiorgi L. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. Hum Mut 2005; 26:94-105.
23. Fukumoto Y, Kaibuchi K, Hori Y, Fujioka H, Araki S, Ueda T, Kikuchi A, Takai Y. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene 1990; 5:1321-8.
24. Olofsson B. Rho guanine dissiociation inhibitors: pivotal molecules in cellular signaling. Cell Signal 1999; 11:545-54.
25. Weis K. Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell 2003; 112:441-51.
26. Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol 2005; 25:4853-62.
27. Jin K, Lim S, Mercer SE, Friedman E. The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling. J Biol Chem 2005; 280:42097-105.
28. Shin I, Kim S, Song H, Kim HR, Moon A. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005; 280:14675-83.
29. Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA. Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem 2004; 279:26176-83.
30. Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
31. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000; 63:111-5.
32. Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, Salminen A, Helisalmi S, Soininen H. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neurosc 2002; 113:301-10.
33. Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 2001; 20:6459-72
34. Huang C, Jacobson K, Schaller MD. A role for JNK-paxillin signaling in cell migration. Cell Cycle 2004; 3:4-6.
35. Fontijn RD, Goud B, Echard A, Jollivet F, van Marle J, Pannekoek H, Horrevoets AJ. The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis. Mol Cell Biol 2001; 21:2944-55.
36. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16:143-63.
37. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H. Specific inhibition of gene expression using a stably integrated, inducible small-interfiring-RNA vector. Embo Rep 2003; 4:609-15.
38. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15:871-5.
39. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 2001; 20:3449-55.
40. Hatfield GW, Hung SP, Baldi P. Differential analysis of DNA microarray gene expression data. Mol Microbiol 2003; 47:871-7.